---

---

tags : Update    source : Www.biospace.com   

save search

---

Marinus Pharmaceuticals Provides Update on the Phase 3 RAISE Trial and Reports Preliminary First Quarter 2024 Financial Results
Published: 2024-04-15 (Crawled : 13:00) - biospace.com/
MRNS | $1.29 -82.85% -482.95% 35M |

Health Technology

| -82.71% | O: -75.4% H: 5.41% C: -29.73%
first update pharmaceuticals trial financial results

---

Vir Biotechnology to Provide Business Update and Report First Quarter 2024 Financial Results on May 2, 2024
Published: 2024-04-11 (Crawled : 23:00) - biospace.com/
VIR | $8.55 -4.68% -4.91% 770K |

Health Technology

| -5.72% | O: 0.99% H: 2.29% C: 0.65%
first report business update financial results

---

Aptevo Therapeutics Provides Pipeline Update
Published: 2024-04-10 (Crawled : 14:00) - biospace.com/
APVO 3 d | $0.7815 -7.53% -8.14% 470K |

Health Technology

| -75.98% | O: -6.44% H: 1.64% C: -21.31%
update pipeline therapeutics

---

BrainStorm Cell Therapeutics to Provide Update on NurOwn Program
Published: 2024-04-08 (Crawled : 12:00) - biospace.com/
BCLI | $0.54 -7.53% -8.15% 570K |

Health Technology

| -18.41% | O: -0.37% H: 0.0% C: 0.0%
update cell nurown program therapeutics

---

StageZero Life Sciences Provides an Update on Application for Management Cease Trade Order
Published: 2024-04-05 (Crawled : 13:30) - biospace.com/
SZLSF | $0.0288 -11.46% 130K |

n/a

| Email alert Add to watchlist
management life update sciences for order application

---

COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE
Published: 2024-04-04 (Crawled : 20:00) - biospace.com/
CLGN | $5.245 2.64% 6.5K |

Health Technology

| -4.7% | O: -0.18% H: 0.0% C: -2.95%
biotechnologies year update financial results

---

COLLPLANT BIOTECHNOLOGIES REPORTS 2023 FULL YEAR FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE - April 4, 2024
Published: 2024-04-04 (Crawled : 12:30) - biospace.com/
CLGN | $5.245 2.64% 6.5K |

Health Technology

| -4.7% | O: -0.18% H: 0.0% C: -2.95%
biotechnologies year update financial results

---

Achilles Therapeutics Provides Interim Phase I/IIa Update on Clonal Neoantigen Reactive T Cells in Advanced NSCLC and Melanoma Including First Patients Dosed with Enhanced Host Conditioning
Published: 2024-04-04 (Crawled : 11:00) - biospace.com/
ACHL | $0.848 -0.24% -0.24% 250K |

Manufacturing

| -29.69% | O: -16.22% H: 0.99% C: -7.89%
first melanoma update therapeutics advanced

---

Amarin Provides Update on VAZKEPA® (Icosapent Ethyl) Intellectual Property Portfolio in EuropeCompany’s IP Protection for VAZKEPA® in Europe Now Extended Into 2039
Published: 2024-04-03 (Crawled : 19:00) - biospace.com/
AMRN | $0.9225 -3.61% -3.74% 620K |

Health Technology

| -7.21% | O: 3.03% H: 8.82% C: 3.92%
vazkepa europe update

---

Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
Published: 2024-04-01 (Crawled : 18:00) - biospace.com/
QNCX | $1.005 6.59% 6.18% 76K |

Professional, Scientific, and T...

| -5.19% | O: 7.55% H: 0.0% C: -4.39%
business update therapeutics financial results

---

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-04-01 (Crawled : 17:00) - biospace.com/
NRXP | $4.9 -4.3% -4.49% 210K |

Manufacturing

| 938.36% | O: 895.97% H: 14.34% C: 11.7%
business year update pharmaceuticals financial results

---

Immunome Reports Full Year 2023 Financial Results and Provides Update on Recently Acquired Assets
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
IMNM | $18.84 -8.46% -9.24% 720K |

Health Technology

| -26.14% | O: 0.04% H: 0.86% C: -3.33%
year update financial acquired results

---

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
NDRA | $0.2653 -28.3% -39.46% 410K |

Health Technology

| -68.06% | O: -2.26% H: 2.92% C: -27.66%
business life year update sciences financial results

---

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate Update
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
SCYX | $1.45 0.35% 0.34% 130K |

Health Technology

| 3.16% | O: -0.35% H: 7.04% C: 3.52%
year update financial results

---

Bristol Myers Squibb Provides Update on the First Phase 3 YELLOWSTONE Trial Evaluating Oral Zeposia (ozanimod) in Patients with Moderate to Severe Active Crohn’s Disease
Published: 2024-03-28 (Crawled : 22:00) - biospace.com/
BMY | $48.51 0.48% 0.0% 12M |

Health Technology

| -8.9% | O: 0.26% H: 2.03% C: 1.57%
first disease active update trial

---

Marinus Pharmaceuticals Comments on Patent Challenge by Ovid Therapeutics Inc. and Provides Update on Marinus’ Post Grant Review
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
OVID | $3.22 0.63% 0.62% 130K |

Health Technology

| 6.67% | O: 1.67% H: 1.64% C: 0.0%
MRNS | $1.29 -82.85% -482.95% 35M |

Health Technology

| -85.21% | O: 0.8% H: 2.37% C: -0.11%
patent review update pharmaceuticals grant therapeutics

---

Adaptive Biotechnologies to Hold a Business Update Conference Call and Webcast on April 2, 2024
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
ADPT | $2.92 -2.99% -3.08% 3.2M |

Commercial Services

| 1.04% | O: 2.43% H: 0.0% C: -2.03%
conference biotechnologies business update

---

Syros Reports Fourth Quarter and Full Year 2023 Financial Results and Provides a Corporate Update
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
SYRS | $5.32 -1.3% -1.32% 150K |

Health Technology

| -14.4% | O: -4.8% H: 3.7% C: -1.85%
year update financial results

---

PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results
Published: 2024-03-27 (Crawled : 00:00) - biospace.com/
PDSB | $2.81 -11.91% -13.52% 1.3M |

Health Technology

| -37.05% | O: -10.71% H: 8.5% C: -3.75%
biotech year update financial results

---

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Business Update
Published: 2024-03-27 (Crawled : 11:00) - biospace.com/
CRBU | $4.07 -3.1% -3.19% 1.6M |

Health Technology

| -19.57% | O: 1.58% H: 0.58% C: -0.39%
NVS | $94.41 0.95% 0.0% 1.4M |

Health Technology

| -0.9% | O: 0.24% H: 0.42% C: 0.4%
LLY | $750.77 -0.12% 0.0% 2.3M |

Health Technology

| -3.11% | O: 0.49% H: 0.84% C: -0.07%
TGTX | $14.08 -0.57% -0.57% 2.3M |

Health Technology

| -8.87% | O: 0.71% H: 0.39% C: 0.13%
DTIL | $13.02 -7.79% -8.45% 110K |

Health Technology

| 2.43% | O: 0.39% H: 4.22% C: 1.41%
precision business year update financial results

---

Gainers vs Losers

49%

51%

Top 10 Gainers

KAVL | $6.275 135.02% 57.45% 44M |

Wholesale Trade

PXMD | $0.7375 79.09% 44.16% 4.5M |

Health Technology

DYNT | $0.371 -5.12% 43.09% 3.3M |

Health Technology

LGVN P 3 d | $2.94 73.96% 42.52% 57M |

HUBC | $1.94 49.23% 32.99% 73M |

n/a

SPCB | $0.4044 46.52% 31.75% 130M |

Electronic Technology

ONVO | $1.34 32.66% 24.62% 54M |

Health Technology

OMQS | $0.6869 32.1% 24.3% 3.6M |

Professional, Scientific, and T...

SNPO | $10.555 29.67% 22.88% 4M |

AMBI | $3.72 -26.77% 21.77% 9.8K |

n/a

---

Your saved searches

---